But, Poles said he felt the study had a higher rate of adverse events than he likes to see, and he'd like to see long-term results. In addition, he noted, because there are other medications with a longer track record already available, he'd be hesitant to prescribe this new drug until he'd exhausted other options first.
"The drug is worthy of further study, but it may not be the panacea we hoped for," Poles said.
Learn more about ulcerative colitis from the U.S. National Library of Medicine.
Copyright © 2012 HealthDay. All rights reserved.